Purpose The aim of this study was to evaluate subfoveal choroidal thickness (SFCT) as a
marker of outcome in real-world treatment of diabetic macular edema (DME) and to correlate
it with choroidal thicknesses (CT) collected around the fovea. Methods Prospective
interventional case series included a total of 126 eyes from 126 patients with recently
diagnosed DME treated with a 3-monthly loading dose of ranibizumab or aflibercept and
PRN thereafter until 24 months (M). CT was manually measured in the central 3500 μm …

Dear Editor: We would like to address several challenges that have arisen from the study by
Campos et al.[1]. There was a selection bias attributable to inclusion in the study of patients
with different forms of non-proliferative diabetic retinopathy (mild/moderate/severe)
diagnosed with recent diabetic macular edema (DME). It should be noted that 50.8% of the
eyes included had a past history of macular photocoagulation (treatment-non-naïve
patients). In addition, the treatments administered to patients were different, namely 113 …